Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 9

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 9
---
. |

| ● | “Kodatef” is the brand name of Arakoda outside the United States. Kodatef has been approved for use in Australia by the Therapeutic Goods Administration. |

| ● | “Legacy Studies” is a reference to the collection of clinical and non-clinical studies involving Tafenoquine, which were conducted by the U.S. Army prior to 2014, and which were included in the new drug application submitted by 60P to the FDA in 2018. Some of those Legacy Studies are described in the account of the Army development program published by Zottig et. al. |

| ● | “Mode of Action” is the process by which an anti-infective or other pharmaceutical product is known or suspected to affect a disease process. This process is different for each drug and may or may not be known at the time of FDA approval. |

| ● | “NIH” means the National Institutes of Health. |

| ● | “RSV” means respiratory syncytial virus, which is a common respiratory virus that usually causes cold-like symptoms. |

| ● | “Spp” is shorthand use to refer to multiple species of organisms in a particular genus. Thus, Candida spp refers collectively to Candida auris, Candida albicans and other Candida species. |

| ● | “Tafenoquine” is the shortened name of the active ingredient of Arakoda and Kodatef, Tafenoquine succinate. |

<div align='center'>iii</div>

| ● | “TGA” is the Therapeutic Goods Administration, the Australian equivalent of the FDA. |

| ● | “Zika” means a mosquito-borne viral disease occurring in tropical and subtropical areas. |

In connection with presentation of scientific
data, this prospectus references “P-values” at various points. These values are provided to convey the likelihood of
a particular set of data occurring by chance. For example, a P-value of 0.12 associated with a stand-alone, pre-conceived hypothesis
is generally understood to mean that the likelihood of that particular outcome occurring purely by chance is 12%. It is scientific convention
that a particular observation is “proven” if its associated P value is lower than 0.05 (i.e., associated with a likelihood
of occurring by chance of < 5%). However, clinical observations of interest are routinely reported in the peer-reviewed scientific
literature even if their associated P-values are >